Abstract
According to evolving guidelines, candidates for HIV preexposure prophylaxis (PrEP) include HIV-uninfected men who have sex with men who engage in condomless anal intercourse, individuals in HIV-serodifferent sexual relationships, those with frequent anogenital sexually transmitted infections, and those who have received repeated nonoccupational postexposure prophylaxis treatment courses. In the real-world setting, indications for PrEP and management of PrEP candidates and patients maybe less than clear-cut. Factors to be considered when assessing candidacy for PrEP and maximizing efficacy of treatment are discussed. This article summarizes a presentation by Demetre C. Daskalakis, MD, MPH, at the IAS-USA continuing education program held in Los Angeles, California, in April 2014.
| Original language | English |
|---|---|
| Pages (from-to) | 670-675 |
| Number of pages | 6 |
| Journal | Topics in antiviral medicine |
| Volume | 22 |
| Issue number | 4 |
| State | Published - 1 Sep 2014 |
Keywords
- Emtricitabine
- HIV
- PREP
- Preexposure prophylaxis
- Risk behavior
- Serodifferent
- Serodiscordant
- Tenofovir